March 2026 - BioMedWire (BMW)

FridayMar 06, 2026 10:00 am

OSU Researchers Develop Nanomaterial That Eliminates Cancer Cells

Oregon State University researchers have engineered a new nanomaterial from iron that kills cancer cells inside tumors and leaves normal cells unaffected. This new nanomaterial works by triggering two chemical reactions inside tumors and the cancer cells die off as a result of these reactions. In a study that appeared in the journal Advanced Functional Materials, the scientists explain that the novel nanomaterial initiates two different chemical reactions that cause oxidative stress to kill cancer cells from the inside. Their work advances the field of chemodynamic therapy, also known as CDT. This field seeks to leverage the unique microenvironment inside tumors by altering the conditions that cancer cells thrive in in order to kill them off by denying the…

FridayMar 06, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents The company is advancing LB-100 through clinical development in collaboration with academic and research institutions Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to…

ThursdayMar 05, 2026 10:00 am

Researchers Say ICE Operations are Harming Public Health

The media has been awash with stories of intense sweeps by Immigration and Customs Enforcement (ICE) conducted in different cities, such as Minneapolis. While a lot of focus has been on the sometimes high-handed methods used during these operations, a team of researchers is drawing attention to the adverse public health effects of these ICE sweeps. University of Iowa’s Asst. Prof. Nicole Novak and Associate Professor William Lopez of the University of Michigan write that these operations have far-reaching effects on public health that take a while to fully come to light, and that it will take years to roll back those adverse effects. One of the effects they point out is that…

ThursdayMar 05, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach

Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. Soligenix’s development of synthetic hypericin illustrates this “one drug, multiple diseases” model in action. HyBryte is being developed to treat both cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin, and psoriasis. Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix…

WednesdayMar 04, 2026 9:45 am

Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform

Earth Science Tech reported fiscal Q3 2026 revenue of $8.4 million, up 14.1% year over year, with gross margin expanding to 76.3% and adjusted EBITDA rising to $1.2 million Management said Peaks, the company’s telemedicine platform, surpassed $2.0 million in revenue in less than a year, while the company pursues additional state licenses to expand its footprint ETST engaged Semple, Marchal and Cooper, LLP as its independent PCAOB auditor, a governance move framed as necessary as consolidated accounting complexity increases Healthcare delivery is being reshaped by two forces that often move at different speeds: consumer demand for faster access and…

TuesdayMar 03, 2026 10:00 am

New Treatment Dramatically Improves Survival for Patients with Deadly Brain Tumors

Researchers at Keck Medicine, University of Southern California (USC) have discovered that combining immunotherapy with laser heat therapy could significantly extend the survival of individuals diagnosed with deadly brain cancers. Astrocytoma, which includes cancers like glioblastoma, grows aggressively and usually recurs after patients have undergone surgery to remove the tumors. This makes the cancer difficult to treat, and patients rarely survive for more than 5 months once diagnosed with high-grade astrocytoma. Immunotherapies, treatments that leverage the body’s immune system to fight cancer, work remarkably well in addressing cancers found in other body parts. However, these treatments exhibit dismal results when used against brain cancers. This is because the blood-brain…

TuesdayMar 03, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

New report upgrades HeartBeam to buy, raises 12-month price target to $4, citing regulatory progress and company’s transition toward commercialization. Joseph Gunnar characterized the FDA clearance of HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment as a “critical regulatory milestone.” The research report underscores the company’s targeted go-to-market strategy. Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing…

MondayMar 02, 2026 9:00 am

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

There are several types of technologies for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others Linac for Image Guided Hadron Therapy, LiGHT system, is believed to offer a more affordable, compact, and efficient design, along with better treatment precision than traditional technologies The system complements LIXTE’s lead clinical candidate, LB-100, which is a small-molecule PP2A inhibitor which is designed to enhance the activity of immunotherapy and chemotherapy Treating tumors with proton therapy is a highly advanced form of radiation that offers high precision, which minimizes radiation exposure for the tissue around the tumor. There…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: March 2026

OSU Researchers Develop Nanomaterial That Eliminates Cancer Cells

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

Researchers Say ICE Operations are Harming Public Health

Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach

Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform

New Treatment Dramatically Improves Survival for Patients with Deadly Brain Tumors

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search